Specify a stock or a cryptocurrency in the search bar to get a summary
Modalis Therapeutics Corp
4883Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. It is developing therapies for genetic diseases using its proprietary CRISPR-GNDM technology that enables to control gene expressions through modulating the switch (epigenetics of a specific locus. The company has a. joint research agreement with JCR Pharmaceuticals Co., Ltd. to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. The company was formerly known as EdiGENE Corporation and changed its name to Modalis Therapeutics Corporation in August 2019. Modalis Therapeutics Corporation was founded in 2016 and is headquartered in Tokyo, Japan. Address: Y?s Building, Tokyo, Japan, 103-0026
Analytics
WallStreet Target Price
138 667.95 JPYP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 4883
Dividend Analytics 4883
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 4883
Stock Valuation 4883
Financials 4883
Results | 2019 | Dynamics |